Cost-effective strategies for the management of vascular disease

Vascular Medicine

Volumn 2, Issue 1, 1997, Pages 25-29

  West, Jeffrey A ^a,b,c  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

Cost effectiveness analysis; Peripheral arterial disease; Prevention

Indexed keywords

ARTICLE; BEHAVIOR MODIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RISK FACTOR; SMOKING CESSATION; SOCIETY; TREATMENT OUTCOME; DYSLIPIDEMIA; ECONOMIC ASPECT; FUNDING; HEALTH CARE COST; HOSPITALIZATION; LIPOGENESIS; MEDICAL SERVICE; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; QUALITY OF LIFE; REVASCULARIZATION; RISK ASSESSMENT; VASCULAR DISEASE;

MEVINOLIN;

EID: 0030839805     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1358863X9700200105     Document Type: Article

References (12)

1. American Heart Association. Heart and stroke facts: 1996 statistical suppl: 2, 23.
2. Goldman L, Cook EF. The decline in ischemic heart disease mortality rates. An analysis of the comparative effects of medical interventions and changes in lifestyle. Ann Intern Med 1984; 101: 825-36.
3. Weinstein MC, Coxson PG, Williams LW, Pass TM, Stason WB, Goldman L. Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model. Am J Public Health 1987; 77: 1417-26.
4. Drummond M, Stoddart G, Labelle R, Cushman R. Health economics: an introduction for clinicians. Ann Intent Med 1987; 107: 88-92.
5. Detsky AS, Naglie IG. A clinician's guide to cost-effectiveness analysis. Ann Intern Med 1990; 113: 147-54.
6. Eisenberg JM. Clinical economics. A guide to the economic analysis of clinical practices. JAMA 1989; 262(20): 2879-86.
7. Kupersmith J, Holmes-Rovner M, Hogan A, Rovner D, Gardiner J. Cost-effectiveness analysis in heart disease, part I: general principles. Prog Cardiovasc Dis 1994; 37(3): 161-84.
8. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, Browner D. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381-86.
9. US Department of Health and Human Services. The health benefits of smoking cessation: a report of the Surgeon General. Washington (DC): Public Health Service, Centers for Disease Control, 1990: no. (CDC) 90-8416.
10. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet 1994; 3-44: 1383-89.
11. Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-38.
12. US Department of Health and Human Services. National Center for Health Statistics: vital statistics of the United States, Volume 2, Section 6: life tables. 1984.